)
Edge3 Apr 2026
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Curanex Pharmaceuticals
Curanex Pharmaceuticals (CURX) investor relations material
Curanex Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary30 Mar, 2026
Executive summary
Completed IPO in August 2025, raising $15M, with an additional $2.25M from over-allotment; shares listed on Nasdaq under CURX.
Focused on developing Phyto-N, a botanical drug candidate for inflammatory diseases, with IND submission for ulcerative colitis targeted for Q4 2026.
No revenue generated in 2025; business model anticipates future revenue from product sales, licensing, and collaborations post-approval.
Expanded R&D activities post-IPO, advancing preclinical and IND-enabling studies for multiple indications.
Financial highlights
Net loss of $4.2M for 2025, up from $0.36M in 2024, driven by increased R&D and G&A expenses.
R&D expenses rose to $3.0M in 2025 from $0.07M in 2024 due to expanded preclinical studies.
G&A expenses increased to $1.25M in 2025 from $0.29M in 2024, reflecting higher payroll and public company costs.
Cash and equivalents at year-end 2025 were $5.0M, up from $0.15M in 2024, primarily from IPO proceeds.
No revenue recognized in 2025 or 2024; future revenue dependent on successful product development and commercialization.
Outlook and guidance
Existing cash expected to fund operations for at least 12 months from the report date.
Plans to submit IND for Phyto-N in ulcerative colitis in Q4 2026, with Phase I trial initiation in Australia.
Additional capital may be required for further clinical development and expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Curanex Pharmaceuticals
- Biotech IPO targets $8M for preclinical trials, with founders retaining majority control.CURX
Registration Filing29 Nov 2025 - IPO aims to fund first clinical trials for a botanical drug, with high risk and insider control.CURXRegistration Filing29 Nov 2025
- Biotech IPO seeks $12.1M for botanical drug trials, with founders retaining majority control.CURXRegistration Filing29 Nov 2025
- IPO aims to fund early clinical trials for a botanical drug, with founders retaining majority control.CURXRegistration Filing29 Nov 2025
- IPO funds early-stage botanical drug development; founders retain majority control.CURXRegistration Filing29 Nov 2025
- IPO targets $12.1M–$14.2M for botanical drug trials; founders retain majority control.CURXRegistration Filing29 Nov 2025
- Biotech IPO targets $8M for botanical drug trials, with high founder control and early-stage risk.CURXRegistration Filing29 Nov 2025
- Raised $15.3M gross in IPO, funding R&D; net loss rose, no revenue, Nasdaq compliance risk.CURXQ3 202517 Nov 2025
Next Curanex Pharmaceuticals earnings date
Q1 202618 May, 2026
Curanex Pharmaceuticals
Next Curanex Pharmaceuticals earnings date
Q1 202618 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage